

# Cortellis Competitive Intelligence

## Find drug SWOT analyses


Cortellis Competitive Intelligence gathers data from hundreds of scientific and commercial sources to provide the information you need when evaluating drugs in your field of research.

SWOT analyses summarize expert insights providing an objective overview of the drug and highlighting areas where improvement may be needed or not. These documents are written by Editorial team to help you identify advantages and disadvantages of competitor drugs and crucial drug data such as:


- highlights from clinical trials,
- adverse events,
- issues with formulation/dosage,
- generic competition expected soon,
- sales trends,
- prescribers' opinions,
- potential new indications,
- and much more.

SWOT analyses are available for the most promising drugs in more than 280 franchises. Just follow these steps:

1. Type the name of the indication or mechanism of action of interest in Quick Search.



2. Apply SWOT analysis filter.



SWOT analyses are written for drugs in Phase III and higher showing promising results in clinical trials and approval process.

### 3. Navigate to Drug report.

tucatinib

Snapshot Highlight  Search Terms & Synonyms < Previous Next >

Latest Press Releases

Latest Event Transcripts

Broker Research Reports

Development Profile

Literature Review

Development Status

Regulatory Designations

Milestones

Chemical Structures

Drug Names

Sales and Forecasts

Clinical Trials

Deals and Patents

**SWOT Analysis**

Change History

Sources

SWOT ANALYSIS

Anticancer EGFR/HER protein kinase inhibitors

Strengths

- Improved progression-free survival (PFS), with a 46% reduction in the risk of disease progression or death, when added to Herceptin plus Xeloda in patients with locally advanced unresectable or metastatic HER2-positive breast cancer previously treated with Herceptin, Perjeta and Kadcyła (primary endpoint of the pivotal phase II HER2CLIMB trial) [\[2207043\]](#)
- Also Improved overall survival (OS), with a 34% reduction in the risk of death (secondary endpoint in HER2CLIMB); median OS was 21.9 vs 17.4 months months [\[2207043\]](#)
- In patients with brain metastases at baseline, the reduction in risk of disease progression or death was 52% (secondary endpoint in HER2CLIMB) [\[2207043\]](#)
- Also showing promise in previously treated HER2-positive metastatic colorectal cancer; in the ongoing phase II MOUNTAINEER trial, initial results showed an overall response rate to tucatinib plus Herceptin of 52.2%; median PFS was 8.1 months and median OS was 18.7 months [\[2199432\]](#), [\[2198519\]](#)
- Orphan Drug status for breast cancer patients with brain metastases,

Weaknesses

- Patients who were ER and/or PR positive benefitted less from the drug in the HER2CLIMB trial in third-line breast cancer, with an OS HR = 0.85 compared to ER/PR-negative patients (OS HR = 0.5) [\[2228049\]](#)
- Grade  $\geq$  3 adverse events in the HER2CLIMB trial included diarrhea (12.9% for tucatinib plus Herceptin and Xeloda, versus 8.6% for Herceptin plus Xeloda), increased aspartate aminotransferase (4.5 versus 0.5%) and increased alanine aminotransferase (5.4 versus 0.5%) [\[2207043\]](#)
- The most frequent adverse events in the HER2CLIMB trial included diarrhea, palmar-plantar erythrodysesthesia syndrome, nausea, fatigue and vomiting [\[2207043\]](#)
- Dosed twice daily [\[1719862\]](#)

Opportunities

- The unprecedented benefit in heavily pretreated HER2-positive breast cancer, including an OS benefit and also for a patient population including those with untreated and progressing brain metastases, indicate the drug will likely become standard of care in third-line

Threats

- Regulatory risk; the drug is not currently approved for any indication. A US filing was submitted in December 2019, and an EU filing was submitted in January 2020 [\[2231443\]](#), [\[2241158\]](#)

SWOT analyses in Cortellis are available for over 1300 drugs.

For more information contact Customer Service at **LS Product Support**